Precompetitive Consensus Building to Facilitate the Use of Digital Health Technologies to Support Parkinson Disease Drug Development through Regulatory Science
暂无分享,去创建一个
Ariel V. Dowling | D. Hill | B. Bloem | G. Roussos | G. Stebbins | E. Dorsey | V. Aggarwal | K. Marek | T. Simuni | M. Frasier | J. Cedarbaum | B. Boroojerdi | K. Taylor | D. Dexter | Michele T. M. Hu | L. Bain | K. Romero | Luis Garcia-Gancedo | E. Dorsey | R. Alexander | M. Meinders | M. Lindemann | N. Zach | D. Stephenson | J. Goldsack | J. Scheeren | N. Mehrotra | Jackson Burton | L. Evers | Susan J. Lee | Susan J. Lee | M. Dockendorf | Reham Badawy | Janice Hitchcock | Roopal Bhatnagar | Josh Cosman | Katherine Fisher | Michael P. Lawton | Michael Minchik | L. Oliva | R. Rubens | Sakshi Sadar | E. Sengoku | Beatrice Yang | George Roussos | M. Hu | Kirsten I. Taylor | L. Garcia-Gancedo | J. Hitchcock | Jesse M. Cedarbaum | Bastiaan R. Bloem | J. C. Goldsack | Michael P. Lawton | S. Sadar
[1] S. Hendrix,et al. Clinically Meaningful Outcomes in Early Alzheimer Disease: A Consortia-Driven Approach to Identifying What Matters to Patients , 2017, Therapeutic innovation & regulatory science.
[2] J. Cedarbaum,et al. Targeted Therapies for Parkinson's Disease: From Genetics to the Clinic , 2018, Movement disorders : official journal of the Movement Disorder Society.
[3] M Daumer,et al. Considerations for development of an evidence dossier to support the use of mobile sensor technology for clinical outcome assessments in clinical trials. , 2020, Contemporary clinical trials.
[4] S. Buckman-Garner,et al. The Role of Public–Private Partnerships in Catalyzing the Critical Path , 2017, Clinical and translational science.
[5] S. Masand,et al. Accelerating Adoption of Patient-Facing Technologies in Clinical Trials: A Pharmaceutical Industry Perspective on Opportunities and Challenges , 2019, Therapeutic innovation & regulatory science.
[6] B. Bloem,et al. The Coronavirus Disease 2019 Crisis as Catalyst for Telemedicine for Chronic Neurological Disorders. , 2020, JAMA neurology.
[7] P. Brown,et al. Predicting motor, cognitive & functional impairment in Parkinson's , 2019, Annals of clinical and translational neurology.
[8] Christine Manta,et al. Digital Measures That Matter to Patients: A Framework to Guide the Selection and Development of Digital Measures of Health , 2020, Digital Biomarkers.
[9] E. Ray Dorsey,et al. Verily and Its Approach to Digital Biomarkers , 2017, Digital Biomarkers.
[10] Ida Sim,et al. Mobile Devices and Health. , 2019, The New England journal of medicine.
[11] D. Berg,et al. Cognitive changes in prodromal Parkinson's disease: A review , 2017, Movement disorders : official journal of the Movement Disorder Society.
[12] R. C. Helmich,et al. The Personalized Parkinson Project: examining disease progression through broad biomarkers in early Parkinson’s disease , 2019, BMC Neurology.
[13] K. Kieburtz,et al. New drugs for Parkinson's disease: The regulatory and clinical development pathways in the United States , 2018, Movement disorders : official journal of the Movement Disorder Society.
[14] Martha Brumfield,et al. The Critical Path Institute: transforming competitors into collaborators , 2014, Nature Reviews Drug Discovery.
[15] B. Bloem,et al. The Emerging Evidence of the Parkinson Pandemic , 2018, Journal of Parkinson's disease.
[16] Francesca Cerreta,et al. Digital technologies for medicines: shaping a framework for success , 2020, Nature reviews. Drug discovery.
[17] Yoshihiro Kokubo,et al. Global, regional, and national burden of Parkinson's disease, 1990–2016: a systematic analysis for the Global Burden of Disease Study 2016 , 2018, The Lancet Neurology.
[18] Anirvan Ghosh,et al. Evaluation of smartphone‐based testing to generate exploratory outcome measures in a phase 1 Parkinson's disease clinical trial , 2018, Movement disorders : official journal of the Movement Disorder Society.
[19] Ariel V. Dowling,et al. Verification, analytical validation, and clinical validation (V3): the foundation of determining fit-for-purpose for Biometric Monitoring Technologies (BioMeTs) , 2020, npj Digital Medicine.
[20] Max A. Little,et al. Technology in Parkinson's disease: Challenges and opportunities , 2016, Movement disorders : official journal of the Movement Disorder Society.
[21] Alberto J Espay,et al. Disease Modification in Parkinson's Disease: Current Approaches, Challenges, and Future Considerations , 2018, Movement disorders : official journal of the Movement Disorder Society.
[22] Z. Mari,et al. The Promise of Telemedicine for Movement Disorders: an Interdisciplinary Approach , 2018, Current Neurology and Neuroscience Reports.
[23] Suchi Saria,et al. Metadata Concepts for Advancing the Use of Digital Health Technologies in Clinical Research. , 2019, Digital biomarkers.
[24] Jacqueline Corrigan-Curay,et al. Real-World Evidence and Real-World Data for Evaluating Drug Safety and Effectiveness. , 2018, JAMA.
[25] K. Taylor,et al. Outcome measures based on digital health technology sensor data: data- and patient-centric approaches , 2020, npj Digital Medicine.
[26] I. Clay,et al. Qualification opinion on stride velocity 95th centile as a secondary endpoint in Duchenne Muscular Dystrophy measured by a valid and suitable wearable device , 2019 .
[27] S. Barlas. The 21st Century Cures Act: FDA Implementation One Year Later: Some Action, Some Results, Some Questions. , 2018, P & T : a peer-reviewed journal for formulary management.
[28] Janet Woodcock,et al. The FDA critical path initiative and its influence on new drug development. , 2008, Annual review of medicine.
[29] John Wilbanks,et al. Indicators of retention in remote digital health studies: a cross-study evaluation of 100,000 participants , 2019, npj Digital Medicine.
[30] Sean Khozin,et al. Developing and adopting safe and effective digital biomarkers to improve patient outcomes , 2019, npj Digital Medicine.
[31] Max A. Little,et al. Smartphone motor testing to distinguish idiopathic REM sleep behavior disorder, controls, and PD , 2018, Neurology.
[32] Shyamal Patel,et al. Clinical feasibility of a wearable, conformable sensor patch to monitor motor symptoms in Parkinson's disease. , 2019, Parkinsonism & related disorders.
[33] M. Ringel,et al. Innovation in Regulatory Science Is Meeting Evolution of Clinical Evidence Generation , 2019, Clinical pharmacology and therapeutics.
[34] Paolo Bonato,et al. A roadmap for implementation of patient‐centered digital outcome measures in Parkinson's disease obtained using mobile health technologies , 2019, Movement disorders : official journal of the Movement Disorder Society.
[35] Cindy Howry,et al. Selection of and Evidentiary Considerations for Wearable Devices and Their Measurements for Use in Regulatory Decision Making: Recommendations from the ePRO Consortium. , 2017, Value in health : the journal of the International Society for Pharmacoeconomics and Outcomes Research.
[36] M. Horne,et al. Evaluation of the Parkinson’s KinetiGraph in monitoring and managing Parkinson’s disease , 2017, Expert review of medical devices.
[37] Dimitrios Athanasiou,et al. European regulators’ views on a wearable-derived performance measurement of ambulation for Duchenne muscular dystrophy regulatory trials , 2019, Neuromuscular Disorders.
[38] Thierry Troosters,et al. Walking-related digital mobility outcomes as clinical trial endpoint measures: protocol for a scoping review , 2020, BMJ Open.
[39] Arthur W. Toga,et al. Precompetitive Data Sharing as a Catalyst to Address Unmet Needs in Parkinson’s Disease , 2015, Journal of Parkinson's disease.
[40] Norbert Schuff,et al. The Parkinson's progression markers initiative (PPMI) – establishing a PD biomarker cohort , 2018, Annals of clinical and translational neurology.
[41] M D Kruizinga,et al. Development of Novel, Value-Based, Digital Endpoints for Clinical Trials: A Structured Approach Toward Fit-for-Purpose Validation , 2020, Pharmacological Reviews.
[42] Thomas Voit,et al. A Movement Monitor Based on Magneto-Inertial Sensors for Non-Ambulant Patients with Duchenne Muscular Dystrophy: A Pilot Study in Controlled Environment , 2016, PloS one.
[43] Z. Mari,et al. Implementation of Telemedicine for Urgent and Ongoing Healthcare for Patients with Parkinson's Disease During the COVID-19 Pandemic: New Expectations for the Future. , 2020, Journal of Parkinson's disease.
[44] R. Roubenoff,et al. How soon will digital endpoints become a cornerstone for future drug development? , 2019, Drug discovery today.
[45] M. Hallett,et al. Past, present, and future of Parkinson's disease: A special essay on the 200th Anniversary of the Shaking Palsy , 2017, Movement disorders : official journal of the Movement Disorder Society.
[46] D. Hill,et al. The Qualification of an Enrichment Biomarker for Clinical Trials Targeting Early Stages of Parkinson’s Disease , 2019, Journal of Parkinson's disease.
[47] Günther Deuschl,et al. The new definition and diagnostic criteria of Parkinson's disease , 2016, The Lancet Neurology.